SCHEMBL735604

SCHEMBL735604

Cc1ccc(C2CCC(=O)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 2/20 0.50
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
MAP1LC3B Q9GZQ8 2/20 0.45
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
CYP19A1 P11511 2/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
SRD5A1 P18405 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
ATM Q13315 2/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SLC18A3 Q16572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004062 1.00 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL7004274 1.00 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL714856 0.89 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL3533675 0.88 ESR2 (0.64) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL428432 0.83 MAP1LC3B (0.55) MAP1LC3BMAPTGAALMNAPOLB
SCHEMBL2047764 0.80 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL14144935 0.80 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL2150282 0.80 ESR2 (0.78) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL444141 0.80 SRD5A1 (0.53) ESR2PDE4APDE4BPDE4CPDE4D
SCHEMBL2295980 0.80 ESR2 (0.50) ESR2PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3183242-B1 SUBSTITUTED BICYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-05-19 EP disclosed
US-8329676-B2 Cycloalkane-containing sphingosine 1-phosphate agonists UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-12-11 US disclosed
US-8138377-B2 Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use DOV PHARMACEUTICAL, INC. (US) 2012-03-20 US disclosed
US-20110245204-A1 CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2011-10-06 US disclosed
US-8008286-B2 Method for treatment of neuropathic pain UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-08-30 US disclosed
EP-2035417-B1 BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES ASTRAZENECA AB (SE) 2011-03-02 EP disclosed
US-20090298898-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2009-12-03 US disclosed
US-20090298898-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2009-12-03 US disclosed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
US-7569727-B2 N-{(4-{3-[2,6-dichloro-4-(3,3-dichloro-allyloxy)-phenoxy]-propoxy}-phenyl)-[(E)-ethoxyimino]-methyl}-2,2,2-trifluoroacetamide; exhibit valuable preventive and/or curative activity even at low rates of concentration, while being well tolerated by warm-blooded animals, fish and plants SYNGENTA CROP PROTECTION, INC. (US) 2009-08-04 US disclosed
US-7569727-B2 N-{(4-{3-[2,6-dichloro-4-(3,3-dichloro-allyloxy)-phenoxy]-propoxy}-phenyl)-[(E)-ethoxyimino]-methyl}-2,2,2-trifluoroacetamide; exhibit valuable preventive and/or curative activity even at low rates of concentration, while being well tolerated by warm-blooded animals, fish and plants SYNGENTA CROP PROTECTION, INC. (US) 2009-08-04 US disclosed
EP-2080752-A1 Pesticidally active ketone and oxime derivatives Syngenta Participations AG (CH) 2009-07-22 EP disclosed
US-20090062238-A1 METHOD FOR TREATMENT OF NEUROPATHIC PAIN UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2009-03-05 US disclosed
US-20080293822-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use ETHISMOS RESEARCH, INC. 2008-11-27 US disclosed
US-20080269348-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use ETHISMOS RESEARCH, INC. 2008-10-30 US disclosed
US-20080200525-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2008-08-21 US disclosed
US-20080200525-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2008-08-21 US disclosed
US-20080194696-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use ETHISMOS RESEARCH, INC. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194696-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use HTR2C, HTR1B, HTR3C ESR2 2740/4885PDE4A 1529/4885PDE4B 971/4885
US-20110245204-A1 CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS S1PR1, S1PR3, S1PR4 ESR2 2108/4885PDE4A 320/4885PDE4B 488/4885
US-20080293822-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use HTR2C, HTR1B, HTR3C ESR2 2740/4885PDE4A 1529/4885PDE4B 971/4885
US-20090298898-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES CHRM2, FOXO3, CHRM1 ESR2 1035/4885PDE4A 3798/4885PDE4B 3815/4885
US-20080269348-A1 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use HTR2C, HTR1B, HTR3C ESR2 2740/4885PDE4A 1529/4885PDE4B 971/4885
US-20090062238-A1 METHOD FOR TREATMENT OF NEUROPATHIC PAIN S1PR2, S1PR1, S1PR4 ESR2 1983/4885PDE4A 199/4885PDE4B 345/4885
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 ESR2 1822/4885PDE4A 2253/4885PDE4B 1677/4885
US-20080200525-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES CHRM2, FOXO3, CHRM1 ESR2 1035/4885PDE4A 3798/4885PDE4B 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.